Global Coagulation Factor IX (Human) Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Coagulation Factor IX (Human) market size was valued at US$ 343 million in 2025 and is forecast to a readjusted size of US$ 460 million by 2032 with a CAGR of 4.2% during review period.
Coagulation Factor IX (Human) is a single-factor plasma-derived blood product manufactured by isolating and purifying factor IX from qualified human plasma, followed by validated viral inactivation or removal processes. It is generally supplied as a white or off-white lyophilized powder and reconstituted into a clear or slightly opalescent solution for intravenous infusion. The active ingredient is human coagulation factor IX, with stabilizers, buffer salts, and other formulation excipients as applicable, and potency is expressed in international units. The product belongs to plasma protein products, antihemorrhagic agents, and coagulation factor replacement therapies. Its key technical requirements include traceable plasma sourcing, protein purification, viral safety control, sterility assurance, lyophilized stability, potency testing, impurity control, and thrombogenicity-related quality control. Mechanistically, Coagulation Factor IX (Human) replaces deficient or missing factor IX in patients and, after activation within the coagulation cascade, participates in factor X activation, thrombin generation, and fibrin clot formation. It is mainly used for the treatment, prevention, and perioperative management of bleeding associated with hemophilia B or factor IX deficiency, subject to the approved label in each jurisdiction.
Market opportunities are mainly supported by the essential treatment needs of hemophilia B patients, improved access to rare disease medicines, broader reimbursement, hospital stockpiling demand, and better utilization of plasma fractions. Although Coagulation Factor IX (Human) serves a small patient population, acute bleeding control, perioperative hemostasis, and selected prophylaxis settings require reliable supply, giving the product resilient demand and strong clinical necessity. For plasma-product manufacturers, it improves the value extracted from coagulation-related plasma fractions and strengthens portfolio synergy with albumin, immunoglobulin, prothrombin complex concentrates, and other hemostatic products. Markets such as China still have room for better clinical access and domestic substitution.
The main challenges are constrained plasma supply, complex manufacturing, strict quality supervision, high batch-consistency requirements, and the direct impact of viral safety, sterility assurance, and thrombogenicity control on product approval and clinical confidence. The product is not being banned or phased out, but traditional plasma-derived preparations face substitution pressure in premium long-term prophylaxis markets. Recombinant factor products, extended half-life recombinant products, non-factor subcutaneous therapies, and gene therapies may divert some patients, especially in markets with strong reimbursement and mature home-treatment systems. As a result, Coagulation Factor IX (Human) will increasingly be positioned around supply security, emergency bleeding control, perioperative management, cost-sensitive markets, and selected replacement-therapy use cases.
Downstream demand is evolving from purely on-demand hemostasis toward a structure combining standardized diagnosis, hospital reserves, perioperative management, and selected long-term prophylaxis. Mature markets focus more on safety records, infusion convenience, real-world effectiveness, and the long-term value of alternative therapies, while emerging markets emphasize supply stability, reimbursement coverage, hospital procurement, and basic treatment availability. Future procurement will place greater weight on cost per unit of potency, batch quality stability, plasma-resource capability, viral safety systems, and continuous supply reliability. Overall, the product is unlikely to disappear quickly, but market growth will be steady rather than high-growth, with competition shifting toward quality, safety, price, and supply-chain strength.
This report is a detailed and comprehensive analysis for global Coagulation Factor IX (Human) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Coagulation Factor IX (Human) market size and forecasts, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (USD/Pcs), 2021-2032
Global Coagulation Factor IX (Human) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (USD/Pcs), 2021-2032
Global Coagulation Factor IX (Human) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (USD/Pcs), 2021-2032
Global Coagulation Factor IX (Human) market shares of main players, shipments in revenue ($ Million), sales quantity (K Pcs), and ASP (USD/Pcs), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Coagulation Factor IX (Human) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Coagulation Factor IX (Human) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Coagulation Factor IX (Human), with price, sales quantity, revenue, and global market share of Coagulation Factor IX (Human) from 2021 to 2026.
Chapter 3, the Coagulation Factor IX (Human) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Coagulation Factor IX (Human) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Coagulation Factor IX (Human) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Coagulation Factor IX (Human).
Chapter 14 and 15, to describe Coagulation Factor IX (Human) sales channel, distributors, customers, research findings and conclusion.
Coagulation Factor IX (Human) is a single-factor plasma-derived blood product manufactured by isolating and purifying factor IX from qualified human plasma, followed by validated viral inactivation or removal processes. It is generally supplied as a white or off-white lyophilized powder and reconstituted into a clear or slightly opalescent solution for intravenous infusion. The active ingredient is human coagulation factor IX, with stabilizers, buffer salts, and other formulation excipients as applicable, and potency is expressed in international units. The product belongs to plasma protein products, antihemorrhagic agents, and coagulation factor replacement therapies. Its key technical requirements include traceable plasma sourcing, protein purification, viral safety control, sterility assurance, lyophilized stability, potency testing, impurity control, and thrombogenicity-related quality control. Mechanistically, Coagulation Factor IX (Human) replaces deficient or missing factor IX in patients and, after activation within the coagulation cascade, participates in factor X activation, thrombin generation, and fibrin clot formation. It is mainly used for the treatment, prevention, and perioperative management of bleeding associated with hemophilia B or factor IX deficiency, subject to the approved label in each jurisdiction.
Market opportunities are mainly supported by the essential treatment needs of hemophilia B patients, improved access to rare disease medicines, broader reimbursement, hospital stockpiling demand, and better utilization of plasma fractions. Although Coagulation Factor IX (Human) serves a small patient population, acute bleeding control, perioperative hemostasis, and selected prophylaxis settings require reliable supply, giving the product resilient demand and strong clinical necessity. For plasma-product manufacturers, it improves the value extracted from coagulation-related plasma fractions and strengthens portfolio synergy with albumin, immunoglobulin, prothrombin complex concentrates, and other hemostatic products. Markets such as China still have room for better clinical access and domestic substitution.
The main challenges are constrained plasma supply, complex manufacturing, strict quality supervision, high batch-consistency requirements, and the direct impact of viral safety, sterility assurance, and thrombogenicity control on product approval and clinical confidence. The product is not being banned or phased out, but traditional plasma-derived preparations face substitution pressure in premium long-term prophylaxis markets. Recombinant factor products, extended half-life recombinant products, non-factor subcutaneous therapies, and gene therapies may divert some patients, especially in markets with strong reimbursement and mature home-treatment systems. As a result, Coagulation Factor IX (Human) will increasingly be positioned around supply security, emergency bleeding control, perioperative management, cost-sensitive markets, and selected replacement-therapy use cases.
Downstream demand is evolving from purely on-demand hemostasis toward a structure combining standardized diagnosis, hospital reserves, perioperative management, and selected long-term prophylaxis. Mature markets focus more on safety records, infusion convenience, real-world effectiveness, and the long-term value of alternative therapies, while emerging markets emphasize supply stability, reimbursement coverage, hospital procurement, and basic treatment availability. Future procurement will place greater weight on cost per unit of potency, batch quality stability, plasma-resource capability, viral safety systems, and continuous supply reliability. Overall, the product is unlikely to disappear quickly, but market growth will be steady rather than high-growth, with competition shifting toward quality, safety, price, and supply-chain strength.
This report is a detailed and comprehensive analysis for global Coagulation Factor IX (Human) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Coagulation Factor IX (Human) market size and forecasts, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (USD/Pcs), 2021-2032
Global Coagulation Factor IX (Human) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (USD/Pcs), 2021-2032
Global Coagulation Factor IX (Human) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (USD/Pcs), 2021-2032
Global Coagulation Factor IX (Human) market shares of main players, shipments in revenue ($ Million), sales quantity (K Pcs), and ASP (USD/Pcs), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Coagulation Factor IX (Human)
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Coagulation Factor IX (Human) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- High-Purity Coagulation Factor IX (Human)
- Intermediate-Purity Coagulation Factor IX (Human)
- Others
- Lyophilized Powder for Solution for Injection
- Liquid Solution for Injection
- Others
- 250 IU and Below
- Above 250 IU to 500 IU
- Above 500 IU to 1000 IU
- Above 1000 IU
- Solvent-Detergent Treated Products
- Virus-Filtered Products
- Heat-Treated or Pasteurized Products
- Multi-Step Viral Inactivation and Removal Products
- Hospital
- Personal Clinic
- Others
- CSL Behring
- Takeda
- Grifols Biologicals
- Octapharma
- Kedrion
- Bio Products Laboratory
- LFB
- Biotest
- KM Biologics
- Intas Pharmaceuticals
- Shandong Taibang Biological Products
- Sichuan Yuanda Shuyang Pharmaceutical
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Coagulation Factor IX (Human) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Coagulation Factor IX (Human), with price, sales quantity, revenue, and global market share of Coagulation Factor IX (Human) from 2021 to 2026.
Chapter 3, the Coagulation Factor IX (Human) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Coagulation Factor IX (Human) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Coagulation Factor IX (Human) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Coagulation Factor IX (Human).
Chapter 14 and 15, to describe Coagulation Factor IX (Human) sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 High-Purity Coagulation Factor IX (Human)
1.3.3 Intermediate-Purity Coagulation Factor IX (Human)
1.3.4 Others
1.4 Market Analysis by Dosage Form
1.4.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
1.4.2 Lyophilized Powder for Solution for Injection
1.4.3 Liquid Solution for Injection
1.4.4 Others
1.5 Market Analysis by Vial Strength
1.5.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Vial Strength: 2021 Versus 2025 Versus 2032
1.5.2 250 IU and Below
1.5.3 Above 250 IU to 500 IU
1.5.4 Above 500 IU to 1000 IU
1.5.5 Above 1000 IU
1.6 Market Analysis by Viral Safety Processing Route
1.6.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Viral Safety Processing Route: 2021 Versus 2025 Versus 2032
1.6.2 Solvent-Detergent Treated Products
1.6.3 Virus-Filtered Products
1.6.4 Heat-Treated or Pasteurized Products
1.6.5 Multi-Step Viral Inactivation and Removal Products
1.7 Market Analysis by Application
1.7.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 Hospital
1.7.3 Personal Clinic
1.7.4 Others
1.8 Global Coagulation Factor IX (Human) Market Size & Forecast
1.8.1 Global Coagulation Factor IX (Human) Consumption Value (2021 & 2025 & 2032)
1.8.2 Global Coagulation Factor IX (Human) Sales Quantity (2021-2032)
1.8.3 Global Coagulation Factor IX (Human) Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 CSL Behring
2.1.1 CSL Behring Details
2.1.2 CSL Behring Major Business
2.1.3 CSL Behring Coagulation Factor IX (Human) Product and Services
2.1.4 CSL Behring Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 CSL Behring Recent Developments/Updates
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business
2.2.3 Takeda Coagulation Factor IX (Human) Product and Services
2.2.4 Takeda Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Takeda Recent Developments/Updates
2.3 Grifols Biologicals
2.3.1 Grifols Biologicals Details
2.3.2 Grifols Biologicals Major Business
2.3.3 Grifols Biologicals Coagulation Factor IX (Human) Product and Services
2.3.4 Grifols Biologicals Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Grifols Biologicals Recent Developments/Updates
2.4 Octapharma
2.4.1 Octapharma Details
2.4.2 Octapharma Major Business
2.4.3 Octapharma Coagulation Factor IX (Human) Product and Services
2.4.4 Octapharma Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Octapharma Recent Developments/Updates
2.5 Kedrion
2.5.1 Kedrion Details
2.5.2 Kedrion Major Business
2.5.3 Kedrion Coagulation Factor IX (Human) Product and Services
2.5.4 Kedrion Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Kedrion Recent Developments/Updates
2.6 Bio Products Laboratory
2.6.1 Bio Products Laboratory Details
2.6.2 Bio Products Laboratory Major Business
2.6.3 Bio Products Laboratory Coagulation Factor IX (Human) Product and Services
2.6.4 Bio Products Laboratory Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Bio Products Laboratory Recent Developments/Updates
2.7 LFB
2.7.1 LFB Details
2.7.2 LFB Major Business
2.7.3 LFB Coagulation Factor IX (Human) Product and Services
2.7.4 LFB Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 LFB Recent Developments/Updates
2.8 Biotest
2.8.1 Biotest Details
2.8.2 Biotest Major Business
2.8.3 Biotest Coagulation Factor IX (Human) Product and Services
2.8.4 Biotest Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Biotest Recent Developments/Updates
2.9 KM Biologics
2.9.1 KM Biologics Details
2.9.2 KM Biologics Major Business
2.9.3 KM Biologics Coagulation Factor IX (Human) Product and Services
2.9.4 KM Biologics Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 KM Biologics Recent Developments/Updates
2.10 Intas Pharmaceuticals
2.10.1 Intas Pharmaceuticals Details
2.10.2 Intas Pharmaceuticals Major Business
2.10.3 Intas Pharmaceuticals Coagulation Factor IX (Human) Product and Services
2.10.4 Intas Pharmaceuticals Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Intas Pharmaceuticals Recent Developments/Updates
2.11 Shandong Taibang Biological Products
2.11.1 Shandong Taibang Biological Products Details
2.11.2 Shandong Taibang Biological Products Major Business
2.11.3 Shandong Taibang Biological Products Coagulation Factor IX (Human) Product and Services
2.11.4 Shandong Taibang Biological Products Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Shandong Taibang Biological Products Recent Developments/Updates
2.12 Sichuan Yuanda Shuyang Pharmaceutical
2.12.1 Sichuan Yuanda Shuyang Pharmaceutical Details
2.12.2 Sichuan Yuanda Shuyang Pharmaceutical Major Business
2.12.3 Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Product and Services
2.12.4 Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: COAGULATION FACTOR IX (HUMAN) BY MANUFACTURER
3.1 Global Coagulation Factor IX (Human) Sales Quantity by Manufacturer (2021-2026)
3.2 Global Coagulation Factor IX (Human) Revenue by Manufacturer (2021-2026)
3.3 Global Coagulation Factor IX (Human) Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Coagulation Factor IX (Human) by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Coagulation Factor IX (Human) Manufacturer Market Share in 2025
3.4.3 Top 6 Coagulation Factor IX (Human) Manufacturer Market Share in 2025
3.5 Coagulation Factor IX (Human) Market: Overall Company Footprint Analysis
3.5.1 Coagulation Factor IX (Human) Market: Region Footprint
3.5.2 Coagulation Factor IX (Human) Market: Company Product Type Footprint
3.5.3 Coagulation Factor IX (Human) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Coagulation Factor IX (Human) Market Size by Region
4.1.1 Global Coagulation Factor IX (Human) Sales Quantity by Region (2021-2032)
4.1.2 Global Coagulation Factor IX (Human) Consumption Value by Region (2021-2032)
4.1.3 Global Coagulation Factor IX (Human) Average Price by Region (2021-2032)
4.2 North America Coagulation Factor IX (Human) Consumption Value (2021-2032)
4.3 Europe Coagulation Factor IX (Human) Consumption Value (2021-2032)
4.4 Asia-Pacific Coagulation Factor IX (Human) Consumption Value (2021-2032)
4.5 South America Coagulation Factor IX (Human) Consumption Value (2021-2032)
4.6 Middle East & Africa Coagulation Factor IX (Human) Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
5.2 Global Coagulation Factor IX (Human) Consumption Value by Type (2021-2032)
5.3 Global Coagulation Factor IX (Human) Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
6.2 Global Coagulation Factor IX (Human) Consumption Value by Application (2021-2032)
6.3 Global Coagulation Factor IX (Human) Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
7.2 North America Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
7.3 North America Coagulation Factor IX (Human) Market Size by Country
7.3.1 North America Coagulation Factor IX (Human) Sales Quantity by Country (2021-2032)
7.3.2 North America Coagulation Factor IX (Human) Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
8.2 Europe Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
8.3 Europe Coagulation Factor IX (Human) Market Size by Country
8.3.1 Europe Coagulation Factor IX (Human) Sales Quantity by Country (2021-2032)
8.3.2 Europe Coagulation Factor IX (Human) Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Coagulation Factor IX (Human) Market Size by Region
9.3.1 Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Coagulation Factor IX (Human) Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
10.2 South America Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
10.3 South America Coagulation Factor IX (Human) Market Size by Country
10.3.1 South America Coagulation Factor IX (Human) Sales Quantity by Country (2021-2032)
10.3.2 South America Coagulation Factor IX (Human) Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Coagulation Factor IX (Human) Market Size by Country
11.3.1 Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Coagulation Factor IX (Human) Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Coagulation Factor IX (Human) Market Drivers
12.2 Coagulation Factor IX (Human) Market Restraints
12.3 Coagulation Factor IX (Human) Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Coagulation Factor IX (Human) and Key Manufacturers
13.2 Manufacturing Costs Percentage of Coagulation Factor IX (Human)
13.3 Coagulation Factor IX (Human) Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Coagulation Factor IX (Human) Typical Distributors
14.3 Coagulation Factor IX (Human) Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 High-Purity Coagulation Factor IX (Human)
1.3.3 Intermediate-Purity Coagulation Factor IX (Human)
1.3.4 Others
1.4 Market Analysis by Dosage Form
1.4.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
1.4.2 Lyophilized Powder for Solution for Injection
1.4.3 Liquid Solution for Injection
1.4.4 Others
1.5 Market Analysis by Vial Strength
1.5.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Vial Strength: 2021 Versus 2025 Versus 2032
1.5.2 250 IU and Below
1.5.3 Above 250 IU to 500 IU
1.5.4 Above 500 IU to 1000 IU
1.5.5 Above 1000 IU
1.6 Market Analysis by Viral Safety Processing Route
1.6.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Viral Safety Processing Route: 2021 Versus 2025 Versus 2032
1.6.2 Solvent-Detergent Treated Products
1.6.3 Virus-Filtered Products
1.6.4 Heat-Treated or Pasteurized Products
1.6.5 Multi-Step Viral Inactivation and Removal Products
1.7 Market Analysis by Application
1.7.1 Overview: Global Coagulation Factor IX (Human) Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 Hospital
1.7.3 Personal Clinic
1.7.4 Others
1.8 Global Coagulation Factor IX (Human) Market Size & Forecast
1.8.1 Global Coagulation Factor IX (Human) Consumption Value (2021 & 2025 & 2032)
1.8.2 Global Coagulation Factor IX (Human) Sales Quantity (2021-2032)
1.8.3 Global Coagulation Factor IX (Human) Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 CSL Behring
2.1.1 CSL Behring Details
2.1.2 CSL Behring Major Business
2.1.3 CSL Behring Coagulation Factor IX (Human) Product and Services
2.1.4 CSL Behring Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 CSL Behring Recent Developments/Updates
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business
2.2.3 Takeda Coagulation Factor IX (Human) Product and Services
2.2.4 Takeda Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Takeda Recent Developments/Updates
2.3 Grifols Biologicals
2.3.1 Grifols Biologicals Details
2.3.2 Grifols Biologicals Major Business
2.3.3 Grifols Biologicals Coagulation Factor IX (Human) Product and Services
2.3.4 Grifols Biologicals Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Grifols Biologicals Recent Developments/Updates
2.4 Octapharma
2.4.1 Octapharma Details
2.4.2 Octapharma Major Business
2.4.3 Octapharma Coagulation Factor IX (Human) Product and Services
2.4.4 Octapharma Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Octapharma Recent Developments/Updates
2.5 Kedrion
2.5.1 Kedrion Details
2.5.2 Kedrion Major Business
2.5.3 Kedrion Coagulation Factor IX (Human) Product and Services
2.5.4 Kedrion Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Kedrion Recent Developments/Updates
2.6 Bio Products Laboratory
2.6.1 Bio Products Laboratory Details
2.6.2 Bio Products Laboratory Major Business
2.6.3 Bio Products Laboratory Coagulation Factor IX (Human) Product and Services
2.6.4 Bio Products Laboratory Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Bio Products Laboratory Recent Developments/Updates
2.7 LFB
2.7.1 LFB Details
2.7.2 LFB Major Business
2.7.3 LFB Coagulation Factor IX (Human) Product and Services
2.7.4 LFB Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 LFB Recent Developments/Updates
2.8 Biotest
2.8.1 Biotest Details
2.8.2 Biotest Major Business
2.8.3 Biotest Coagulation Factor IX (Human) Product and Services
2.8.4 Biotest Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Biotest Recent Developments/Updates
2.9 KM Biologics
2.9.1 KM Biologics Details
2.9.2 KM Biologics Major Business
2.9.3 KM Biologics Coagulation Factor IX (Human) Product and Services
2.9.4 KM Biologics Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 KM Biologics Recent Developments/Updates
2.10 Intas Pharmaceuticals
2.10.1 Intas Pharmaceuticals Details
2.10.2 Intas Pharmaceuticals Major Business
2.10.3 Intas Pharmaceuticals Coagulation Factor IX (Human) Product and Services
2.10.4 Intas Pharmaceuticals Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Intas Pharmaceuticals Recent Developments/Updates
2.11 Shandong Taibang Biological Products
2.11.1 Shandong Taibang Biological Products Details
2.11.2 Shandong Taibang Biological Products Major Business
2.11.3 Shandong Taibang Biological Products Coagulation Factor IX (Human) Product and Services
2.11.4 Shandong Taibang Biological Products Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Shandong Taibang Biological Products Recent Developments/Updates
2.12 Sichuan Yuanda Shuyang Pharmaceutical
2.12.1 Sichuan Yuanda Shuyang Pharmaceutical Details
2.12.2 Sichuan Yuanda Shuyang Pharmaceutical Major Business
2.12.3 Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Product and Services
2.12.4 Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: COAGULATION FACTOR IX (HUMAN) BY MANUFACTURER
3.1 Global Coagulation Factor IX (Human) Sales Quantity by Manufacturer (2021-2026)
3.2 Global Coagulation Factor IX (Human) Revenue by Manufacturer (2021-2026)
3.3 Global Coagulation Factor IX (Human) Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Coagulation Factor IX (Human) by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Coagulation Factor IX (Human) Manufacturer Market Share in 2025
3.4.3 Top 6 Coagulation Factor IX (Human) Manufacturer Market Share in 2025
3.5 Coagulation Factor IX (Human) Market: Overall Company Footprint Analysis
3.5.1 Coagulation Factor IX (Human) Market: Region Footprint
3.5.2 Coagulation Factor IX (Human) Market: Company Product Type Footprint
3.5.3 Coagulation Factor IX (Human) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Coagulation Factor IX (Human) Market Size by Region
4.1.1 Global Coagulation Factor IX (Human) Sales Quantity by Region (2021-2032)
4.1.2 Global Coagulation Factor IX (Human) Consumption Value by Region (2021-2032)
4.1.3 Global Coagulation Factor IX (Human) Average Price by Region (2021-2032)
4.2 North America Coagulation Factor IX (Human) Consumption Value (2021-2032)
4.3 Europe Coagulation Factor IX (Human) Consumption Value (2021-2032)
4.4 Asia-Pacific Coagulation Factor IX (Human) Consumption Value (2021-2032)
4.5 South America Coagulation Factor IX (Human) Consumption Value (2021-2032)
4.6 Middle East & Africa Coagulation Factor IX (Human) Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
5.2 Global Coagulation Factor IX (Human) Consumption Value by Type (2021-2032)
5.3 Global Coagulation Factor IX (Human) Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
6.2 Global Coagulation Factor IX (Human) Consumption Value by Application (2021-2032)
6.3 Global Coagulation Factor IX (Human) Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
7.2 North America Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
7.3 North America Coagulation Factor IX (Human) Market Size by Country
7.3.1 North America Coagulation Factor IX (Human) Sales Quantity by Country (2021-2032)
7.3.2 North America Coagulation Factor IX (Human) Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
8.2 Europe Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
8.3 Europe Coagulation Factor IX (Human) Market Size by Country
8.3.1 Europe Coagulation Factor IX (Human) Sales Quantity by Country (2021-2032)
8.3.2 Europe Coagulation Factor IX (Human) Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Coagulation Factor IX (Human) Market Size by Region
9.3.1 Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Coagulation Factor IX (Human) Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
10.2 South America Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
10.3 South America Coagulation Factor IX (Human) Market Size by Country
10.3.1 South America Coagulation Factor IX (Human) Sales Quantity by Country (2021-2032)
10.3.2 South America Coagulation Factor IX (Human) Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Coagulation Factor IX (Human) Market Size by Country
11.3.1 Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Coagulation Factor IX (Human) Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Coagulation Factor IX (Human) Market Drivers
12.2 Coagulation Factor IX (Human) Market Restraints
12.3 Coagulation Factor IX (Human) Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Coagulation Factor IX (Human) and Key Manufacturers
13.2 Manufacturing Costs Percentage of Coagulation Factor IX (Human)
13.3 Coagulation Factor IX (Human) Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Coagulation Factor IX (Human) Typical Distributors
14.3 Coagulation Factor IX (Human) Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Coagulation Factor IX (Human) Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Coagulation Factor IX (Human) Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 3. Global Coagulation Factor IX (Human) Consumption Value by Vial Strength, (USD Million), 2021 & 2025 & 2032
Table 4. Global Coagulation Factor IX (Human) Consumption Value by Viral Safety Processing Route, (USD Million), 2021 & 2025 & 2032
Table 5. Global Coagulation Factor IX (Human) Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 7. CSL Behring Major Business
Table 8. CSL Behring Coagulation Factor IX (Human) Product and Services
Table 9. CSL Behring Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. CSL Behring Recent Developments/Updates
Table 11. Takeda Basic Information, Manufacturing Base and Competitors
Table 12. Takeda Major Business
Table 13. Takeda Coagulation Factor IX (Human) Product and Services
Table 14. Takeda Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 15. Takeda Recent Developments/Updates
Table 16. Grifols Biologicals Basic Information, Manufacturing Base and Competitors
Table 17. Grifols Biologicals Major Business
Table 18. Grifols Biologicals Coagulation Factor IX (Human) Product and Services
Table 19. Grifols Biologicals Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 20. Grifols Biologicals Recent Developments/Updates
Table 21. Octapharma Basic Information, Manufacturing Base and Competitors
Table 22. Octapharma Major Business
Table 23. Octapharma Coagulation Factor IX (Human) Product and Services
Table 24. Octapharma Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Octapharma Recent Developments/Updates
Table 26. Kedrion Basic Information, Manufacturing Base and Competitors
Table 27. Kedrion Major Business
Table 28. Kedrion Coagulation Factor IX (Human) Product and Services
Table 29. Kedrion Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Kedrion Recent Developments/Updates
Table 31. Bio Products Laboratory Basic Information, Manufacturing Base and Competitors
Table 32. Bio Products Laboratory Major Business
Table 33. Bio Products Laboratory Coagulation Factor IX (Human) Product and Services
Table 34. Bio Products Laboratory Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Bio Products Laboratory Recent Developments/Updates
Table 36. LFB Basic Information, Manufacturing Base and Competitors
Table 37. LFB Major Business
Table 38. LFB Coagulation Factor IX (Human) Product and Services
Table 39. LFB Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. LFB Recent Developments/Updates
Table 41. Biotest Basic Information, Manufacturing Base and Competitors
Table 42. Biotest Major Business
Table 43. Biotest Coagulation Factor IX (Human) Product and Services
Table 44. Biotest Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Biotest Recent Developments/Updates
Table 46. KM Biologics Basic Information, Manufacturing Base and Competitors
Table 47. KM Biologics Major Business
Table 48. KM Biologics Coagulation Factor IX (Human) Product and Services
Table 49. KM Biologics Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. KM Biologics Recent Developments/Updates
Table 51. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 52. Intas Pharmaceuticals Major Business
Table 53. Intas Pharmaceuticals Coagulation Factor IX (Human) Product and Services
Table 54. Intas Pharmaceuticals Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Intas Pharmaceuticals Recent Developments/Updates
Table 56. Shandong Taibang Biological Products Basic Information, Manufacturing Base and Competitors
Table 57. Shandong Taibang Biological Products Major Business
Table 58. Shandong Taibang Biological Products Coagulation Factor IX (Human) Product and Services
Table 59. Shandong Taibang Biological Products Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Shandong Taibang Biological Products Recent Developments/Updates
Table 61. Sichuan Yuanda Shuyang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 62. Sichuan Yuanda Shuyang Pharmaceutical Major Business
Table 63. Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Product and Services
Table 64. Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Sichuan Yuanda Shuyang Pharmaceutical Recent Developments/Updates
Table 66. Global Coagulation Factor IX (Human) Sales Quantity by Manufacturer (2021-2026) & (K Pcs)
Table 67. Global Coagulation Factor IX (Human) Revenue by Manufacturer (2021-2026) & (USD Million)
Table 68. Global Coagulation Factor IX (Human) Average Price by Manufacturer (2021-2026) & (USD/Pcs)
Table 69. Market Position of Manufacturers in Coagulation Factor IX (Human), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 70. Head Office and Coagulation Factor IX (Human) Production Site of Key Manufacturer
Table 71. Coagulation Factor IX (Human) Market: Company Product Type Footprint
Table 72. Coagulation Factor IX (Human) Market: Company Product Application Footprint
Table 73. Coagulation Factor IX (Human) New Market Entrants and Barriers to Market Entry
Table 74. Coagulation Factor IX (Human) Mergers, Acquisition, Agreements, and Collaborations
Table 75. Global Coagulation Factor IX (Human) Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 76. Global Coagulation Factor IX (Human) Sales Quantity by Region (2021-2026) & (K Pcs)
Table 77. Global Coagulation Factor IX (Human) Sales Quantity by Region (2027-2032) & (K Pcs)
Table 78. Global Coagulation Factor IX (Human) Consumption Value by Region (2021-2026) & (USD Million)
Table 79. Global Coagulation Factor IX (Human) Consumption Value by Region (2027-2032) & (USD Million)
Table 80. Global Coagulation Factor IX (Human) Average Price by Region (2021-2026) & (USD/Pcs)
Table 81. Global Coagulation Factor IX (Human) Average Price by Region (2027-2032) & (USD/Pcs)
Table 82. Global Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 83. Global Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 84. Global Coagulation Factor IX (Human) Consumption Value by Type (2021-2026) & (USD Million)
Table 85. Global Coagulation Factor IX (Human) Consumption Value by Type (2027-2032) & (USD Million)
Table 86. Global Coagulation Factor IX (Human) Average Price by Type (2021-2026) & (USD/Pcs)
Table 87. Global Coagulation Factor IX (Human) Average Price by Type (2027-2032) & (USD/Pcs)
Table 88. Global Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 89. Global Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 90. Global Coagulation Factor IX (Human) Consumption Value by Application (2021-2026) & (USD Million)
Table 91. Global Coagulation Factor IX (Human) Consumption Value by Application (2027-2032) & (USD Million)
Table 92. Global Coagulation Factor IX (Human) Average Price by Application (2021-2026) & (USD/Pcs)
Table 93. Global Coagulation Factor IX (Human) Average Price by Application (2027-2032) & (USD/Pcs)
Table 94. North America Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 95. North America Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 96. North America Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 97. North America Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 98. North America Coagulation Factor IX (Human) Sales Quantity by Country (2021-2026) & (K Pcs)
Table 99. North America Coagulation Factor IX (Human) Sales Quantity by Country (2027-2032) & (K Pcs)
Table 100. North America Coagulation Factor IX (Human) Consumption Value by Country (2021-2026) & (USD Million)
Table 101. North America Coagulation Factor IX (Human) Consumption Value by Country (2027-2032) & (USD Million)
Table 102. Europe Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 103. Europe Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 104. Europe Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 105. Europe Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 106. Europe Coagulation Factor IX (Human) Sales Quantity by Country (2021-2026) & (K Pcs)
Table 107. Europe Coagulation Factor IX (Human) Sales Quantity by Country (2027-2032) & (K Pcs)
Table 108. Europe Coagulation Factor IX (Human) Consumption Value by Country (2021-2026) & (USD Million)
Table 109. Europe Coagulation Factor IX (Human) Consumption Value by Country (2027-2032) & (USD Million)
Table 110. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 111. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 112. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 113. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 114. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Region (2021-2026) & (K Pcs)
Table 115. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Region (2027-2032) & (K Pcs)
Table 116. Asia-Pacific Coagulation Factor IX (Human) Consumption Value by Region (2021-2026) & (USD Million)
Table 117. Asia-Pacific Coagulation Factor IX (Human) Consumption Value by Region (2027-2032) & (USD Million)
Table 118. South America Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 119. South America Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 120. South America Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 121. South America Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 122. South America Coagulation Factor IX (Human) Sales Quantity by Country (2021-2026) & (K Pcs)
Table 123. South America Coagulation Factor IX (Human) Sales Quantity by Country (2027-2032) & (K Pcs)
Table 124. South America Coagulation Factor IX (Human) Consumption Value by Country (2021-2026) & (USD Million)
Table 125. South America Coagulation Factor IX (Human) Consumption Value by Country (2027-2032) & (USD Million)
Table 126. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 127. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 128. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 129. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 130. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Country (2021-2026) & (K Pcs)
Table 131. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Country (2027-2032) & (K Pcs)
Table 132. Middle East & Africa Coagulation Factor IX (Human) Consumption Value by Country (2021-2026) & (USD Million)
Table 133. Middle East & Africa Coagulation Factor IX (Human) Consumption Value by Country (2027-2032) & (USD Million)
Table 134. Coagulation Factor IX (Human) Raw Material
Table 135. Key Manufacturers of Coagulation Factor IX (Human) Raw Materials
Table 136. Coagulation Factor IX (Human) Typical Distributors
Table 137. Coagulation Factor IX (Human) Typical Customers
Table 1. Global Coagulation Factor IX (Human) Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Coagulation Factor IX (Human) Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 3. Global Coagulation Factor IX (Human) Consumption Value by Vial Strength, (USD Million), 2021 & 2025 & 2032
Table 4. Global Coagulation Factor IX (Human) Consumption Value by Viral Safety Processing Route, (USD Million), 2021 & 2025 & 2032
Table 5. Global Coagulation Factor IX (Human) Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 7. CSL Behring Major Business
Table 8. CSL Behring Coagulation Factor IX (Human) Product and Services
Table 9. CSL Behring Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. CSL Behring Recent Developments/Updates
Table 11. Takeda Basic Information, Manufacturing Base and Competitors
Table 12. Takeda Major Business
Table 13. Takeda Coagulation Factor IX (Human) Product and Services
Table 14. Takeda Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 15. Takeda Recent Developments/Updates
Table 16. Grifols Biologicals Basic Information, Manufacturing Base and Competitors
Table 17. Grifols Biologicals Major Business
Table 18. Grifols Biologicals Coagulation Factor IX (Human) Product and Services
Table 19. Grifols Biologicals Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 20. Grifols Biologicals Recent Developments/Updates
Table 21. Octapharma Basic Information, Manufacturing Base and Competitors
Table 22. Octapharma Major Business
Table 23. Octapharma Coagulation Factor IX (Human) Product and Services
Table 24. Octapharma Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Octapharma Recent Developments/Updates
Table 26. Kedrion Basic Information, Manufacturing Base and Competitors
Table 27. Kedrion Major Business
Table 28. Kedrion Coagulation Factor IX (Human) Product and Services
Table 29. Kedrion Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Kedrion Recent Developments/Updates
Table 31. Bio Products Laboratory Basic Information, Manufacturing Base and Competitors
Table 32. Bio Products Laboratory Major Business
Table 33. Bio Products Laboratory Coagulation Factor IX (Human) Product and Services
Table 34. Bio Products Laboratory Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Bio Products Laboratory Recent Developments/Updates
Table 36. LFB Basic Information, Manufacturing Base and Competitors
Table 37. LFB Major Business
Table 38. LFB Coagulation Factor IX (Human) Product and Services
Table 39. LFB Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. LFB Recent Developments/Updates
Table 41. Biotest Basic Information, Manufacturing Base and Competitors
Table 42. Biotest Major Business
Table 43. Biotest Coagulation Factor IX (Human) Product and Services
Table 44. Biotest Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Biotest Recent Developments/Updates
Table 46. KM Biologics Basic Information, Manufacturing Base and Competitors
Table 47. KM Biologics Major Business
Table 48. KM Biologics Coagulation Factor IX (Human) Product and Services
Table 49. KM Biologics Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. KM Biologics Recent Developments/Updates
Table 51. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 52. Intas Pharmaceuticals Major Business
Table 53. Intas Pharmaceuticals Coagulation Factor IX (Human) Product and Services
Table 54. Intas Pharmaceuticals Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Intas Pharmaceuticals Recent Developments/Updates
Table 56. Shandong Taibang Biological Products Basic Information, Manufacturing Base and Competitors
Table 57. Shandong Taibang Biological Products Major Business
Table 58. Shandong Taibang Biological Products Coagulation Factor IX (Human) Product and Services
Table 59. Shandong Taibang Biological Products Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Shandong Taibang Biological Products Recent Developments/Updates
Table 61. Sichuan Yuanda Shuyang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 62. Sichuan Yuanda Shuyang Pharmaceutical Major Business
Table 63. Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Product and Services
Table 64. Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Sichuan Yuanda Shuyang Pharmaceutical Recent Developments/Updates
Table 66. Global Coagulation Factor IX (Human) Sales Quantity by Manufacturer (2021-2026) & (K Pcs)
Table 67. Global Coagulation Factor IX (Human) Revenue by Manufacturer (2021-2026) & (USD Million)
Table 68. Global Coagulation Factor IX (Human) Average Price by Manufacturer (2021-2026) & (USD/Pcs)
Table 69. Market Position of Manufacturers in Coagulation Factor IX (Human), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 70. Head Office and Coagulation Factor IX (Human) Production Site of Key Manufacturer
Table 71. Coagulation Factor IX (Human) Market: Company Product Type Footprint
Table 72. Coagulation Factor IX (Human) Market: Company Product Application Footprint
Table 73. Coagulation Factor IX (Human) New Market Entrants and Barriers to Market Entry
Table 74. Coagulation Factor IX (Human) Mergers, Acquisition, Agreements, and Collaborations
Table 75. Global Coagulation Factor IX (Human) Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 76. Global Coagulation Factor IX (Human) Sales Quantity by Region (2021-2026) & (K Pcs)
Table 77. Global Coagulation Factor IX (Human) Sales Quantity by Region (2027-2032) & (K Pcs)
Table 78. Global Coagulation Factor IX (Human) Consumption Value by Region (2021-2026) & (USD Million)
Table 79. Global Coagulation Factor IX (Human) Consumption Value by Region (2027-2032) & (USD Million)
Table 80. Global Coagulation Factor IX (Human) Average Price by Region (2021-2026) & (USD/Pcs)
Table 81. Global Coagulation Factor IX (Human) Average Price by Region (2027-2032) & (USD/Pcs)
Table 82. Global Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 83. Global Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 84. Global Coagulation Factor IX (Human) Consumption Value by Type (2021-2026) & (USD Million)
Table 85. Global Coagulation Factor IX (Human) Consumption Value by Type (2027-2032) & (USD Million)
Table 86. Global Coagulation Factor IX (Human) Average Price by Type (2021-2026) & (USD/Pcs)
Table 87. Global Coagulation Factor IX (Human) Average Price by Type (2027-2032) & (USD/Pcs)
Table 88. Global Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 89. Global Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 90. Global Coagulation Factor IX (Human) Consumption Value by Application (2021-2026) & (USD Million)
Table 91. Global Coagulation Factor IX (Human) Consumption Value by Application (2027-2032) & (USD Million)
Table 92. Global Coagulation Factor IX (Human) Average Price by Application (2021-2026) & (USD/Pcs)
Table 93. Global Coagulation Factor IX (Human) Average Price by Application (2027-2032) & (USD/Pcs)
Table 94. North America Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 95. North America Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 96. North America Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 97. North America Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 98. North America Coagulation Factor IX (Human) Sales Quantity by Country (2021-2026) & (K Pcs)
Table 99. North America Coagulation Factor IX (Human) Sales Quantity by Country (2027-2032) & (K Pcs)
Table 100. North America Coagulation Factor IX (Human) Consumption Value by Country (2021-2026) & (USD Million)
Table 101. North America Coagulation Factor IX (Human) Consumption Value by Country (2027-2032) & (USD Million)
Table 102. Europe Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 103. Europe Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 104. Europe Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 105. Europe Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 106. Europe Coagulation Factor IX (Human) Sales Quantity by Country (2021-2026) & (K Pcs)
Table 107. Europe Coagulation Factor IX (Human) Sales Quantity by Country (2027-2032) & (K Pcs)
Table 108. Europe Coagulation Factor IX (Human) Consumption Value by Country (2021-2026) & (USD Million)
Table 109. Europe Coagulation Factor IX (Human) Consumption Value by Country (2027-2032) & (USD Million)
Table 110. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 111. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 112. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 113. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 114. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Region (2021-2026) & (K Pcs)
Table 115. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity by Region (2027-2032) & (K Pcs)
Table 116. Asia-Pacific Coagulation Factor IX (Human) Consumption Value by Region (2021-2026) & (USD Million)
Table 117. Asia-Pacific Coagulation Factor IX (Human) Consumption Value by Region (2027-2032) & (USD Million)
Table 118. South America Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 119. South America Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 120. South America Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 121. South America Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 122. South America Coagulation Factor IX (Human) Sales Quantity by Country (2021-2026) & (K Pcs)
Table 123. South America Coagulation Factor IX (Human) Sales Quantity by Country (2027-2032) & (K Pcs)
Table 124. South America Coagulation Factor IX (Human) Consumption Value by Country (2021-2026) & (USD Million)
Table 125. South America Coagulation Factor IX (Human) Consumption Value by Country (2027-2032) & (USD Million)
Table 126. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Type (2021-2026) & (K Pcs)
Table 127. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Type (2027-2032) & (K Pcs)
Table 128. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Application (2021-2026) & (K Pcs)
Table 129. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Application (2027-2032) & (K Pcs)
Table 130. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Country (2021-2026) & (K Pcs)
Table 131. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity by Country (2027-2032) & (K Pcs)
Table 132. Middle East & Africa Coagulation Factor IX (Human) Consumption Value by Country (2021-2026) & (USD Million)
Table 133. Middle East & Africa Coagulation Factor IX (Human) Consumption Value by Country (2027-2032) & (USD Million)
Table 134. Coagulation Factor IX (Human) Raw Material
Table 135. Key Manufacturers of Coagulation Factor IX (Human) Raw Materials
Table 136. Coagulation Factor IX (Human) Typical Distributors
Table 137. Coagulation Factor IX (Human) Typical Customers
LIST OF FIGURES
Figure 1. Coagulation Factor IX (Human) Picture
Figure 2. Global Coagulation Factor IX (Human) Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Coagulation Factor IX (Human) Revenue Market Share by Type in 2025
Figure 4. High-Purity Coagulation Factor IX (Human) Examples
Figure 5. Intermediate-Purity Coagulation Factor IX (Human) Examples
Figure 6. Others Examples
Figure 7. Global Coagulation Factor IX (Human) Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Coagulation Factor IX (Human) Revenue Market Share by Dosage Form in 2025
Figure 9. Lyophilized Powder for Solution for Injection Examples
Figure 10. Liquid Solution for Injection Examples
Figure 11. Others Examples
Figure 12. Global Coagulation Factor IX (Human) Revenue by Vial Strength, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Coagulation Factor IX (Human) Revenue Market Share by Vial Strength in 2025
Figure 14. 250 IU and Below Examples
Figure 15. Above 250 IU to 500 IU Examples
Figure 16. Above 500 IU to 1000 IU Examples
Figure 17. Above 1000 IU Examples
Figure 18. Global Coagulation Factor IX (Human) Revenue by Viral Safety Processing Route, (USD Million), 2021 & 2025 & 2032
Figure 19. Global Coagulation Factor IX (Human) Revenue Market Share by Viral Safety Processing Route in 2025
Figure 20. Solvent-Detergent Treated Products Examples
Figure 21. Virus-Filtered Products Examples
Figure 22. Heat-Treated or Pasteurized Products Examples
Figure 23. Multi-Step Viral Inactivation and Removal Products Examples
Figure 24. Global Coagulation Factor IX (Human) Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 25. Global Coagulation Factor IX (Human) Revenue Market Share by Application in 2025
Figure 26. Hospital Examples
Figure 27. Personal Clinic Examples
Figure 28. Others Examples
Figure 29. Global Coagulation Factor IX (Human) Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 30. Global Coagulation Factor IX (Human) Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 31. Global Coagulation Factor IX (Human) Sales Quantity (2021-2032) & (K Pcs)
Figure 32. Global Coagulation Factor IX (Human) Price (2021-2032) & (USD/Pcs)
Figure 33. Global Coagulation Factor IX (Human) Sales Quantity Market Share by Manufacturer in 2025
Figure 34. Global Coagulation Factor IX (Human) Revenue Market Share by Manufacturer in 2025
Figure 35. Producer Shipments of Coagulation Factor IX (Human) by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 36. Top 3 Coagulation Factor IX (Human) Manufacturer (Revenue) Market Share in 2025
Figure 37. Top 6 Coagulation Factor IX (Human) Manufacturer (Revenue) Market Share in 2025
Figure 38. Global Coagulation Factor IX (Human) Sales Quantity Market Share by Region (2021-2032)
Figure 39. Global Coagulation Factor IX (Human) Consumption Value Market Share by Region (2021-2032)
Figure 40. North America Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 41. Europe Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 42. Asia-Pacific Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 43. South America Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 44. Middle East & Africa Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 45. Global Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 46. Global Coagulation Factor IX (Human) Consumption Value Market Share by Type (2021-2032)
Figure 47. Global Coagulation Factor IX (Human) Average Price by Type (2021-2032) & (USD/Pcs)
Figure 48. Global Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 49. Global Coagulation Factor IX (Human) Revenue Market Share by Application (2021-2032)
Figure 50. Global Coagulation Factor IX (Human) Average Price by Application (2021-2032) & (USD/Pcs)
Figure 51. North America Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 52. North America Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 53. North America Coagulation Factor IX (Human) Sales Quantity Market Share by Country (2021-2032)
Figure 54. North America Coagulation Factor IX (Human) Consumption Value Market Share by Country (2021-2032)
Figure 55. United States Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 56. Canada Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 57. Mexico Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 58. Europe Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 59. Europe Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 60. Europe Coagulation Factor IX (Human) Sales Quantity Market Share by Country (2021-2032)
Figure 61. Europe Coagulation Factor IX (Human) Consumption Value Market Share by Country (2021-2032)
Figure 62. Germany Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 63. France Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 64. United Kingdom Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 65. Russia Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 66. Italy Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 67. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 68. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 69. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity Market Share by Region (2021-2032)
Figure 70. Asia-Pacific Coagulation Factor IX (Human) Consumption Value Market Share by Region (2021-2032)
Figure 71. China Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 72. Japan Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 73. South Korea Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 74. India Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 75. Southeast Asia Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 76. Australia Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 77. South America Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 78. South America Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 79. South America Coagulation Factor IX (Human) Sales Quantity Market Share by Country (2021-2032)
Figure 80. South America Coagulation Factor IX (Human) Consumption Value Market Share by Country (2021-2032)
Figure 81. Brazil Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 82. Argentina Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 83. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 84. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 85. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity Market Share by Country (2021-2032)
Figure 86. Middle East & Africa Coagulation Factor IX (Human) Consumption Value Market Share by Country (2021-2032)
Figure 87. Turkey Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 88. Egypt Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 89. Saudi Arabia Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 90. South Africa Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 91. Coagulation Factor IX (Human) Market Drivers
Figure 92. Coagulation Factor IX (Human) Market Restraints
Figure 93. Coagulation Factor IX (Human) Market Trends
Figure 94. Porters Five Forces Analysis
Figure 95. Manufacturing Cost Structure Analysis of Coagulation Factor IX (Human) in 2025
Figure 96. Manufacturing Process Analysis of Coagulation Factor IX (Human)
Figure 97. Coagulation Factor IX (Human) Industrial Chain
Figure 98. Sales Channel: Direct to End-User vs Distributors
Figure 99. Direct Channel Pros & Cons
Figure 100. Indirect Channel Pros & Cons
Figure 101. Methodology
Figure 102. Research Process and Data Source
Figure 1. Coagulation Factor IX (Human) Picture
Figure 2. Global Coagulation Factor IX (Human) Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Coagulation Factor IX (Human) Revenue Market Share by Type in 2025
Figure 4. High-Purity Coagulation Factor IX (Human) Examples
Figure 5. Intermediate-Purity Coagulation Factor IX (Human) Examples
Figure 6. Others Examples
Figure 7. Global Coagulation Factor IX (Human) Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Coagulation Factor IX (Human) Revenue Market Share by Dosage Form in 2025
Figure 9. Lyophilized Powder for Solution for Injection Examples
Figure 10. Liquid Solution for Injection Examples
Figure 11. Others Examples
Figure 12. Global Coagulation Factor IX (Human) Revenue by Vial Strength, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Coagulation Factor IX (Human) Revenue Market Share by Vial Strength in 2025
Figure 14. 250 IU and Below Examples
Figure 15. Above 250 IU to 500 IU Examples
Figure 16. Above 500 IU to 1000 IU Examples
Figure 17. Above 1000 IU Examples
Figure 18. Global Coagulation Factor IX (Human) Revenue by Viral Safety Processing Route, (USD Million), 2021 & 2025 & 2032
Figure 19. Global Coagulation Factor IX (Human) Revenue Market Share by Viral Safety Processing Route in 2025
Figure 20. Solvent-Detergent Treated Products Examples
Figure 21. Virus-Filtered Products Examples
Figure 22. Heat-Treated or Pasteurized Products Examples
Figure 23. Multi-Step Viral Inactivation and Removal Products Examples
Figure 24. Global Coagulation Factor IX (Human) Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 25. Global Coagulation Factor IX (Human) Revenue Market Share by Application in 2025
Figure 26. Hospital Examples
Figure 27. Personal Clinic Examples
Figure 28. Others Examples
Figure 29. Global Coagulation Factor IX (Human) Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 30. Global Coagulation Factor IX (Human) Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 31. Global Coagulation Factor IX (Human) Sales Quantity (2021-2032) & (K Pcs)
Figure 32. Global Coagulation Factor IX (Human) Price (2021-2032) & (USD/Pcs)
Figure 33. Global Coagulation Factor IX (Human) Sales Quantity Market Share by Manufacturer in 2025
Figure 34. Global Coagulation Factor IX (Human) Revenue Market Share by Manufacturer in 2025
Figure 35. Producer Shipments of Coagulation Factor IX (Human) by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 36. Top 3 Coagulation Factor IX (Human) Manufacturer (Revenue) Market Share in 2025
Figure 37. Top 6 Coagulation Factor IX (Human) Manufacturer (Revenue) Market Share in 2025
Figure 38. Global Coagulation Factor IX (Human) Sales Quantity Market Share by Region (2021-2032)
Figure 39. Global Coagulation Factor IX (Human) Consumption Value Market Share by Region (2021-2032)
Figure 40. North America Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 41. Europe Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 42. Asia-Pacific Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 43. South America Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 44. Middle East & Africa Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 45. Global Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 46. Global Coagulation Factor IX (Human) Consumption Value Market Share by Type (2021-2032)
Figure 47. Global Coagulation Factor IX (Human) Average Price by Type (2021-2032) & (USD/Pcs)
Figure 48. Global Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 49. Global Coagulation Factor IX (Human) Revenue Market Share by Application (2021-2032)
Figure 50. Global Coagulation Factor IX (Human) Average Price by Application (2021-2032) & (USD/Pcs)
Figure 51. North America Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 52. North America Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 53. North America Coagulation Factor IX (Human) Sales Quantity Market Share by Country (2021-2032)
Figure 54. North America Coagulation Factor IX (Human) Consumption Value Market Share by Country (2021-2032)
Figure 55. United States Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 56. Canada Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 57. Mexico Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 58. Europe Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 59. Europe Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 60. Europe Coagulation Factor IX (Human) Sales Quantity Market Share by Country (2021-2032)
Figure 61. Europe Coagulation Factor IX (Human) Consumption Value Market Share by Country (2021-2032)
Figure 62. Germany Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 63. France Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 64. United Kingdom Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 65. Russia Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 66. Italy Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 67. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 68. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 69. Asia-Pacific Coagulation Factor IX (Human) Sales Quantity Market Share by Region (2021-2032)
Figure 70. Asia-Pacific Coagulation Factor IX (Human) Consumption Value Market Share by Region (2021-2032)
Figure 71. China Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 72. Japan Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 73. South Korea Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 74. India Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 75. Southeast Asia Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 76. Australia Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 77. South America Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 78. South America Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 79. South America Coagulation Factor IX (Human) Sales Quantity Market Share by Country (2021-2032)
Figure 80. South America Coagulation Factor IX (Human) Consumption Value Market Share by Country (2021-2032)
Figure 81. Brazil Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 82. Argentina Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 83. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity Market Share by Type (2021-2032)
Figure 84. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity Market Share by Application (2021-2032)
Figure 85. Middle East & Africa Coagulation Factor IX (Human) Sales Quantity Market Share by Country (2021-2032)
Figure 86. Middle East & Africa Coagulation Factor IX (Human) Consumption Value Market Share by Country (2021-2032)
Figure 87. Turkey Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 88. Egypt Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 89. Saudi Arabia Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 90. South Africa Coagulation Factor IX (Human) Consumption Value (2021-2032) & (USD Million)
Figure 91. Coagulation Factor IX (Human) Market Drivers
Figure 92. Coagulation Factor IX (Human) Market Restraints
Figure 93. Coagulation Factor IX (Human) Market Trends
Figure 94. Porters Five Forces Analysis
Figure 95. Manufacturing Cost Structure Analysis of Coagulation Factor IX (Human) in 2025
Figure 96. Manufacturing Process Analysis of Coagulation Factor IX (Human)
Figure 97. Coagulation Factor IX (Human) Industrial Chain
Figure 98. Sales Channel: Direct to End-User vs Distributors
Figure 99. Direct Channel Pros & Cons
Figure 100. Indirect Channel Pros & Cons
Figure 101. Methodology
Figure 102. Research Process and Data Source
